Production Commenced — What It Means
NGL Fine-Chem Limited has successfully operationalised Phase II of its Greenfield manufacturing facility at Tarapur, Maharashtra, as of September 24, 2026. This development follows the Phase I commencement in March 2025, bringing the entire site into full commercial production. The facility represents a strategic augmentation of the company's infrastructure, designed to handle a broad range of Active Pharmaceutical Ingredients.
By completing this phase, the company has finalized its planned expansion at this site, providing the necessary scale to support its evolving product portfolio and diverse manufacturing requirements.
Path to This Milestone
- Total capital expenditure for the Greenfield project reached approximately ₹222 crore by the completion date
- The investment was financed through a mix of ₹138 crore from internal accruals and ₹84 crore via bank term loans
- Phase I of the facility was commissioned on March 11, 2025, serving as the foundation for this expansion
- The site is engineered for flexible manufacturing, allowing for variations in batch sizes and cycle times across different product types
Revenue Impact
The new capacity addition is intended to be utilized flexibly across the company’s diverse API product portfolio, allowing for optimizations based on manufacturing schedules and plant resources. Given that NGL Fine-Chem reported a 33.57 percent year-on-year quarterly revenue growth and a TTM revenue of ₹536.16 crore, the full operationalisation of the Tarapur site provides a framework for sustained volume increases. The company’s PEG ratio of 0.18, compared to the sector average of 2.88, highlights a growth-oriented financial profile as it integrates this new high-value infrastructure into its core operations.
Business Overview
NGL Fine-Chem is a specialized manufacturer of Active Pharmaceutical Ingredients and intermediates, with a significant footprint in both veterinary and human healthcare segments. The company’s product line includes anthelmintics, anti-protozoals, and various other therapeutic categories. By managing different manufacturing processes and yields across its facilities, the company maintains a versatile production environment.
The Tarapur Greenfield expansion is central to the company’s strategy of deepening its presence in the global pharmaceutical supply chain while maintaining a high promoter holding of 72.49 percent.
Financial Context
NGL Fine-Chem's financial performance has shown significant momentum, with net profit growing 127.83 percent annually. The company operates with an operating profit margin of 16.73 percent as of the latest quarter. The successful deployment of ₹222 crore into the Tarapur facility is reflected in the company's asset-heavy growth strategy, supported by a Piotroski Score of 6.
While the debt-to-equity component includes ₹84 crore in term loans, the majority of the expansion was self-funded, indicating robust internal cash flow generation from its existing pharmaceutical operations.
